Royalty Pharma (RPRX) stock
Last close $68.45 on 2026-11-20 (+1.08%) · Sector: Healthcare
Royalty Pharma is a company that buys the rights to future royalty payments from medicines that are already sold or are in late-stage development. It earns money by collecting a share of the sales from those drugs, without having to run the research or manufacturing itself.
Royalty Pharma's business has been steady, with revenue rising to $0.69 billion in the latest quarter and an operating margin of 57.1%, meaning it keeps a large share of each dollar it brings in as operating profit. Over the past year the stock returned 72.2% versus 3.15% for the S&P 500, so it beat the broader market. The stock sits 2.7% below its 52-week high and has risen after each of its last four earnings reports. Insiders sold $32.6 million of stock over the last 90 days and made no purchases, which is worth watching.
Key numbers
- Market cap: $38.1B
- Revenue (last 12 months): $2.61B
- Revenue growth: +11.1%
- Operating margin: 57.1%
- P/E: 44.7
- P/S: 14.6
- Debt to equity: 0.77
- Current ratio: 1.30
Quality score
Overall 42/100 · growth 39 · profitability 89 · financial health 40 · value 0
Performance and risk
1-year return +72.2% vs S&P 500 +3.1% · volatility 22.0% (S&P 500 14.2%) · largest drop -12.1% · beta 0.21
Stock move the day after earnings
- 2026-02-11: +0.1%
- 2026-05-06: +0.6%
- 2026-08-05: +0.5%
- 2026-11-04: +1.7%
Insider trades (12 months)
Bought $0.0M · sold $111.0M
RPRX stock research · RPRX options calculator · Stocks to buy, hold or sell today
StrikeWright provides AI signals only, not financial advice.